Monthly
US$200
Billed every month
Phenylephrine Hydrochloride Injection(盐酸去氧肾上腺素注射液)
Companies, stages and changes, with each record available on this page.
Last 90 days: Accepted: 2 applications
Current coverage may be incomplete
Which companies are listed, and at what stages?
Each source is counted separately. Expand a list to inspect companies, identifiers, dates and sources.
Company names, approval identifiers and strengths are retained as recorded in the Chinese sources. Category labels include the original wording for verification.
Catalogue holders22View records ↓
Under-review filings5View records ↓
This year’s generic filers3View records ↓
NHSA approval numbers29View records ↓
API companies with A status10View records ↓
Chemical-drug catalogue
Loaded records: 22 holders; 1 in the quality-and-efficacy consistency-evaluation category, and 21 in the new chemical-registration-classification generic category. Category counts may overlap.
| Marketing authorization holder | Manufacturer | Approval number | Approved | Strength / specification | Catalogue category (source text) | View source |
|---|---|---|---|---|---|---|
| 上海炫鑫医药科技有限公司 | 山东方明药业集团股份有限公司 | 国药准字H20263044 | 2026/01/05 | 5ml:0.5mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 浙江博崤生物制药有限公司 | 浙江博崤生物制药有限公司 | 国药准字H20256087 | 2025/11/25 | 1ml:10mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 北京海一药业有限公司 | 广东星昊药业有限公司 | 国药准字H20255187 | 2025/08/26 | 5ml：0.5mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 成都苑东生物制药股份有限公司 | 成都苑东生物制药股份有限公司 | 国药准字H20258164 | 2025/08/21 | 1ml:10mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| Mankind Pharma Limited | Mankind Pharma Limited | 国药准字HJ20250091 | 2025/07/29 | 1ml∶10mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 珠海前列药业有限公司 | 湖南华纳大药厂股份有限公司 | 国药准字H20254858 | 2025/07/15 | 5ml：0.5mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 珠海前列药业有限公司 | 湖南华纳大药厂股份有限公司 | 国药准字H20254857 | 2025/07/15 | 1ml：10mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 中润药业有限公司 | 广东星昊药业有限公司 | 国药准字H20258118 | 2025/07/01 | 5ml:0.5mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 德全药品（江苏）股份有限公司 | 德全药品（江苏）股份有限公司 | 国药准字H20254496 | 2025/06/10 | 1ml：10mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 安徽恒星制药有限公司 | 安徽恒星制药有限公司 | 国药准字H20254431 | 2025/06/03 | 5ml：0.5mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 安徽长江药业有限公司 | 安徽长江药业有限公司 | 国药准字H20254136 | 2025/05/13 | 1ml:10mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 海南普利制药股份有限公司 | 海南普利制药股份有限公司 | 国药准字H20253246 | 2025/01/24 | 1ml：10mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 海南普利制药股份有限公司 | 海南普利制药股份有限公司 | 国药准字H20253247 | 2025/01/24 | 10ml：100mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 海南倍特药业有限公司 | 海南倍特药业有限公司 | 国药准字H20249840 | 2024/12/25 | 1ml∶10mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 海南倍特药业有限公司 | 海南倍特药业有限公司 | 国药准字H20249841 | 2024/12/25 | 5ml∶0.5mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 中玉制药（海口）有限公司 | 广东星昊药业有限公司 | 国药准字H20249726 | 2024/12/10 | 1ml：10mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 山东威智百科药业有限公司 | 山东威智百科药业有限公司 | 国药准字H20249727 | 2024/12/10 | 5ml：0.5mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 南京恒道医药科技股份有限公司 | 江苏大红鹰恒顺药业有限公司 | 国药准字H20249211 | 2024/10/29 | 1ml:10mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 石家庄四药有限公司 | 石家庄四药有限公司 | 国药准字H20249214 | 2024/10/29 | 1ml：10mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 南京海融医药科技股份有限公司 | 南京海融制药有限公司 | 国药准字H20243723 | 2024/05/15 | 5ml:0.5mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 南京海融医药科技股份有限公司 | 南京海融制药有限公司 | 国药准字H20243722 | 2024/05/15 | 1ml:10mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 成都瑞尔医药科技有限公司 | 四川美大康佳乐药业有限公司 | 国药准字H20243673 | 2024/05/08 | 1ml:10mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 成都瑞尔医药科技有限公司 | 四川美大康佳乐药业有限公司 | 国药准字H20243674 | 2024/05/08 | 5ml:0.5mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 舒美奇成都生物科技有限公司 | 四川美大康佳乐药业有限公司 | 国药准字H20243558 | 2024/04/24 | 5ml:0.5mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 舒美奇成都生物科技有限公司 | 四川美大康佳乐药业有限公司 | 国药准字H20243559 | 2024/04/24 | 1ml:10mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 上海禾丰制药有限公司 | 上海禾丰制药有限公司 | 国药准字H31021175 | 2023/08/10 | 1ml:10mg | Drug that passed quality-and-efficacy consistency evaluation (通过质量和疗效一致性评价的药品) | CDE |
| 中润药业有限公司 | 广东星昊药业有限公司 | 国药准字H20233385 | 2023/03/24 | 1ml:10mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 合肥亿帆生物制药有限公司 | 合肥亿帆生物制药有限公司 | 国药准字H20233387 | 2023/03/24 | 1ml:10mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 成都苑东生物制药股份有限公司 | 成都苑东生物制药股份有限公司 | 国药准字H20223286 | 2022/05/10 | 5ml:0.5mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 云南龙海天然植物药业有限公司 | 云南龙海天然植物药业有限公司 | 国药准字H20255469 | 2025/09/09 | 5ml︰0.5mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
Distinct full holder names; manufacturers are used only where the holder is unstated. The catalogue covers only part of the chemical-drug market. Categories are counted as recorded, not as a complete market census.
NHSA drug codes
Loaded records: 29 distinct approval numbers and 21 companies.
| Company / applicant | Approval number | Strength / specification | NHSA class | NHSA drug code | View source |
|---|---|---|---|---|---|
| 上海禾丰制药有限公司 | 国药准字H31021175 | 1ml:10mg | Category B (乙) | XC01CAQ130B002010100673 | NHSA |
| 德全药品(江苏)股份有限公司 | 国药准字H20254496 | 1ml:10mg | Category B (乙) | XC01CAQ130B002010101751 | NHSA |
| 成都苑东生物制药股份有限公司 | 国药准字H20223286 | 5ml:0.5mg | Category B (乙) | XC01CAQ130B002010102181 | NHSA |
| 中润药业有限公司 | 国药准字H20258118 | 5ml:0.5mg | Category B (乙) | XC01CAQ130B002010102699 | NHSA |
| 石家庄四药有限公司 | 国药准字H20249214 | 1ml:10mg | Category B (乙) | XC01CAQ130B002010102763 | NHSA |
| 安徽长江药业有限公司 | 国药准字H20254136 | 1ml:10mg | Category B (乙) | XC01CAQ130B002010104451 | NHSA |
| 海南倍特药业有限公司 | 国药准字H20249841 | 5ml∶0.5mg | Category B (乙) | XC01CAQ130B002010105791 | NHSA |
| 海南普利制药股份有限公司 | 国药准字H20253246 | 1ml:10mg | Category B (乙) | XC01CAQ130B002010105801 | NHSA |
| 云南龙海天然植物药业有限公司 | 国药准字H20255469 | 5ml:0.5mg | Category B (乙) | XC01CAQ130B002010106286 | NHSA |
| 安徽恒星制药有限公司 | 国药准字H20254431 | 5ml:0.5mg | Category B (乙) | XC01CAQ130B002010107478 | NHSA |
| 合肥亿帆生物制药有限公司 | 国药准字H20233387 | 1ml:10mg | Category B (乙) | XC01CAQ130B002010182719 | NHSA |
| 南京恒道医药科技股份有限公司 | 国药准字H20249211 | 1ml:10mg | Category B (乙) | XC01CAQ130B002010183035 | NHSA |
| 山东威智百科药业有限公司 | 国药准字H20249727 | 5ml:0.5mg | Category B (乙) | XC01CAQ130B002010183124 | NHSA |
| 中玉制药(海口)有限公司 | 国药准字H20249726 | 1ml:10mg | Category B (乙) | XC01CAQ130B002010183237 | NHSA |
| 中润药业有限公司 | 国药准字H20233385 | 1ml:10mg | Category B (乙) | XC01CAQ130B002010183256 | NHSA |
| 舒美奇成都生物科技有限公司 | 国药准字H20243558 | 5ml:0.5mg | Category B (乙) | XC01CAQ130B002010183337 | NHSA |
| 远大医药(中国)有限公司 | 国药准字H20253388 | 1ml:10mg | Category B (乙) | XC01CAQ130B002010183383 | NHSA |
| 南京海融制药有限公司 | 国药准字H20243722 | 1ml∶10mg | Category B (乙) | XC01CAQ130B002010183564 | NHSA |
| 成都瑞尔医药科技有限公司 | 国药准字H20243673 | 1ml:10mg | Category B (乙) | XC01CAQ130B002010184534 | NHSA |
| 北京海一药业有限公司 | 国药准字H20255187 | 5ml:0.5mg | Category B (乙) | XC01CAQ130B002010185058 | NHSA |
| 珠海前列药业有限公司 | 国药准字H20254857 | 1ml:10mg | Category B (乙) | XC01CAQ130B002010185087 | NHSA |
| Mankind Pharma Limited | 国药准字HJ20250091 | 1ml:10mg | Category B (乙) | XC01CAQ130B002010185454 | NHSA |
| 上海禾丰制药有限公司 | 国药准字H31021175 | 1ml:10mg | Category B (乙) | XC01CAQ130B002010200673 | NHSA |
| 德全药品(江苏)股份有限公司 | 国药准字H20254496 | 1ml:10mg | Category B (乙) | XC01CAQ130B002010201751 | NHSA |
| 成都苑东生物制药股份有限公司 | 国药准字H20223286 | 5ml:0.5mg | Category B (乙) | XC01CAQ130B002010202181 | NHSA |
| 石家庄四药有限公司 | 国药准字H20249214 | 1ml:10mg | Category B (乙) | XC01CAQ130B002010202763 | NHSA |
| 安徽长江药业有限公司 | 国药准字H20254136 | 1ml:10mg | Category B (乙) | XC01CAQ130B002010204451 | NHSA |
| 海南倍特药业有限公司 | 国药准字H20249841 | 5ml∶0.5mg | Category B (乙) | XC01CAQ130B002010205791 | NHSA |
| 海南普利制药股份有限公司 | 国药准字H20253246 | 1ml:10mg | Category B (乙) | XC01CAQ130B002010205801 | NHSA |
| 云南龙海天然植物药业有限公司 | 国药准字H20255469 | 5ml:0.5mg | Category B (乙) | XC01CAQ130B002010206286 | NHSA |
| 安徽恒星制药有限公司 | 国药准字H20254431 | 5ml:0.5mg | Category B (乙) | XC01CAQ130B002010207478 | NHSA |
| 合肥亿帆生物制药有限公司 | 国药准字H20233387 | 1ml:10mg | Category B (乙) | XC01CAQ130B002010282719 | NHSA |
| 南京恒道医药科技股份有限公司 | 国药准字H20249211 | 1ml:10mg | Category B (乙) | XC01CAQ130B002010283035 | NHSA |
| 中润药业有限公司 | 国药准字H20233385 | 1ml:10mg | Category B (乙) | XC01CAQ130B002010283256 | NHSA |
| 舒美奇成都生物科技有限公司 | 国药准字H20243558 | 5ml:0.5mg | Category B (乙) | XC01CAQ130B002010283337 | NHSA |
| 南京海融制药有限公司 | 国药准字H20243722 | 1ml∶10mg | Category B (乙) | XC01CAQ130B002010283564 | NHSA |
| 成都瑞尔医药科技有限公司 | 国药准字H20243673 | 1ml:10mg | Category B (乙) | XC01CAQ130B002010284534 | NHSA |
| Mankind Pharma Limited | 国药准字HJ20250091 | 1ml:10mg | Category B (乙) | XC01CAQ130B002010285454 | NHSA |
| 上海禾丰制药有限公司 | 国药准字H31021175 | 1ml:10mg | Category B (乙) | XC01CAQ130B002010300673 | NHSA |
| 海南普利制药股份有限公司 | 国药准字H20253246 | 1ml:10mg | Category B (乙) | XC01CAQ130B002010305801 | NHSA |
| 中润药业有限公司 | 国药准字H20233385 | 1ml:10mg | Category B (乙) | XC01CAQ130B002010383256 | NHSA |
| 南京海融制药有限公司 | 国药准字H20243722 | 1ml∶10mg | Category B (乙) | XC01CAQ130B002010383564 | NHSA |
| 海南普利制药股份有限公司 | 国药准字H20253246 | 1ml:10mg | Category B (乙) | XC01CAQ130B002010405801 | NHSA |
| 成都苑东生物制药股份有限公司 | 国药准字H20258164 | 1ml:10mg | Category B (乙) | XC01CAQ130B002020102181 | NHSA |
| 海南倍特药业有限公司 | 国药准字H20249840 | 1ml∶10mg | Category B (乙) | XC01CAQ130B002020105791 | NHSA |
| 海南普利制药股份有限公司 | 国药准字H20253247 | 10ml:100mg | Category B (乙) | XC01CAQ130B002020105801 | NHSA |
| 舒美奇成都生物科技有限公司 | 国药准字H20243559 | 1ml:10mg | Category B (乙) | XC01CAQ130B002020183337 | NHSA |
| 南京海融制药有限公司 | 国药准字H20243723 | 5ml:0.5mg | Category B (乙) | XC01CAQ130B002020183564 | NHSA |
| 成都瑞尔医药科技有限公司 | 国药准字H20243674 | 5ml:0.5mg | Category B (乙) | XC01CAQ130B002020184534 | NHSA |
| 珠海前列药业有限公司 | 国药准字H20254858 | 5ml:0.5mg | Category B (乙) | XC01CAQ130B002020185087 | NHSA |
| 成都苑东生物制药股份有限公司 | 国药准字H20258164 | 1ml:10mg | Category B (乙) | XC01CAQ130B002020202181 | NHSA |
| 舒美奇成都生物科技有限公司 | 国药准字H20243559 | 1ml:10mg | Category B (乙) | XC01CAQ130B002020283337 | NHSA |
| 南京海融制药有限公司 | 国药准字H20243723 | 5ml:0.5mg | Category B (乙) | XC01CAQ130B002020283564 | NHSA |
| 成都瑞尔医药科技有限公司 | 国药准字H20243674 | 5ml:0.5mg | Category B (乙) | XC01CAQ130B002020284534 | NHSA |
| 成都苑东生物制药股份有限公司 | 国药准字H20258164 | 1ml:10mg | Category B (乙) | XC01CAQ130B002020302181 | NHSA |
| 南京海融制药有限公司 | 国药准字H20243723 | 5ml:0.5mg | Category B (乙) | XC01CAQ130B002020383564 | NHSA |
| 海南倍特药业有限公司 | 国药准字H20249840 | 1ml∶10mg | Category B (乙) | XC01CAQ130B002030105791 | NHSA |
Approval numbers and companies are deduplicated separately; packaging records remain individually listed. An empty insurance class means it is unstated. NHSA codes supply no approval date and do not establish the outcome of an acceptance number.
Current under-review applications
Loaded records: 5 filings and 3 distinct first applicants.
Generic 5
| Company / applicant | Acceptance number | Application type | Accepted | Strength / specification | View source |
|---|---|---|---|---|---|
| 江苏福邦药业有限公司 | CYHS2602101 | Generic | 2026/08/24 | Not stated by source | CDE |
| 江苏福邦药业有限公司 | CYHS2602100 | Generic | 2026/08/24 | Not stated by source | CDE |
| 广州市联瑞制药有限公司 | CYHS2600381 | Generic | 2026/02/05 | Not stated by source | CDE |
| 绪必迪药业（沧州）有限公司;河北凯威制药有限责任公司 | CYHS2600259 | Generic | 2026/01/23 | Not stated by source | CDE |
| 绪必迪药业（沧州）有限公司;河北凯威制药有限责任公司 | CYHS2600258 | Generic | 2026/01/23 | Not stated by source | CDE |
New generic filings in 2026
Loaded records: 5 filings and 3 distinct first applicants.
| Company / applicant | Acceptance number | Application type | Accepted | Strength / specification | View source |
|---|---|---|---|---|---|
| 江苏福邦药业有限公司 | CYHS2602101 | Generic | 2026/08/24 | Not stated by source | CDE |
| 江苏福邦药业有限公司 | CYHS2602100 | Generic | 2026/08/24 | Not stated by source | CDE |
| 广州市联瑞制药有限公司 | CYHS2600381 | Generic | 2026/02/05 | Not stated by source | CDE |
| 绪必迪药业（沧州）有限公司;河北凯威制药有限责任公司 | CYHS2600259 | Generic | 2026/01/23 | Not stated by source | CDE |
| 绪必迪药业（沧州）有限公司;河北凯威制药有限责任公司 | CYHS2600258 | Generic | 2026/01/23 | Not stated by source | CDE |
API registrations
Non-component matches: 10 companies with A status and 2 I-status records. Component matches are listed separately and excluded from these counts.
| Name | Company / applicant | Registration number | Status | Name match | Source update date | View source |
|---|---|---|---|---|---|---|
| 盐酸去氧肾上腺素 | 湖南华纳大药厂手性药物有限公司 | Y20260000025 | I | Exact ingredient | 2026/02/12 | CDE |
| 盐酸去氧肾上腺素 | 绪必迪药业（沧州）有限公司 | Y20250000477 | I | Exact ingredient | 2025/05/22 | CDE |
| 盐酸去氧肾上腺素 | 武汉武药制药有限公司 | Y20240000593 | A | Exact ingredient | 2026/01/14 | CDE |
| 盐酸去氧肾上腺素 | 湖北美林药业有限公司 | Y20240000416 | A | Exact ingredient | 2025/12/17 | CDE |
| 盐酸去氧肾上腺素 | 浙江博崤生物制药有限公司 | Y20240000091 | A | Exact ingredient | 2025/11/22 | CDE |
| 盐酸去氧肾上腺素 | 安徽恒星制药有限公司 | Y20230000387 | A | Exact ingredient | 2025/03/19 | CDE |
| 盐酸去氧肾上腺素 | 河北广祥制药有限公司 | Y20220001108 | A | Exact ingredient | 2025/07/16 | CDE |
| 盐酸去氧肾上腺素 | Malladi Drugs & Pharmaceuticals Limited | Y20210000760 | A | Exact ingredient | 2025/01/15 | CDE |
| 盐酸去氧肾上腺素 | 深圳沃兰德药业有限公司 | Y20190009335 | A | Exact ingredient | 2026/03/26 | CDE |
| 盐酸去氧肾上腺素 | 赤峰艾克制药科技股份有限公司 | Y20190004873 | A | Exact ingredient | 2024/10/10 | CDE |
| 盐酸去氧肾上腺素 | 浙江海翔川南药业有限公司 | Y20170001393 | A | Exact ingredient | 2024/04/10 | CDE |
| 盐酸去氧肾上腺素 | DIVI'S LABORATORIES LTD | Y20170000948 | A | Exact ingredient | 2026/09/12 | CDE |
A/I are source statuses. Matching uses exact ingredients, salt-normalized names and maintained combination components, without fuzzy matching. A-status companies are deduplicated by the first registered company. Components are excluded from headline counts; the register does not identify the associated formulation.
What changed recently?
Last 90 days, ordered by fact date. Marketing approvals, trial registrations, supplements, notices and review changes are labelled separately.
Trial registration does not mean an application will follow.
This product is outside the trial-registration backfill scope. New registrations after daily collection started remain in scope. Historical rows may also be found by another product search; neither implies complete historical coverage for this product.
NHSA edition maintained to 2026-10-23; latest successful catalogue check: 2026/11/10 07:23. NHSA records lack approval dates; only an earlier edition or observation establishes precedence.
-
2026/08/24Accepted
-
2026/08/24Accepted
How current is each source?
- CDE acceptances and review
- Last successful update: 2026/11/10 07:27
- Chemical-drug catalogue
- Last successful update: 2026/11/10 07:23
Distinct full holder names; manufacturers are used only where the holder is unstated. The catalogue covers only part of the chemical-drug market. Categories are counted as recorded, not as a complete market census.
- Full API register
- Last successful update: 2026/11/10 07:25
- NHSA drug codes
- Last successful update: 2026/11/05 06:45
The fully loaded edition was maintained to 2026-10-23. Publication lags maintenance: the verified 2026-10-16 edition was published on 10-28, a 12-day gap. This is not a fixed lag for every edition.
- NMPA drug delivery notices
- Last successful update: 2026/11/10 18:31
First index-page publication dates: 2026-10-26 to 2026-11-10; 0 pages pending. Covers loaded notices only, not a complete historical approval database.
- Drug Clinical Trial Registry and Information Disclosure Platform
- Last successful update: 2026/11/10 08:10 · Current coverage may be incomplete
Daily collection reads new registrations. Backfill covers registration numbers from 2025 onward (CTR2025/CTR2026), not first-publication years. States are dated observations; revisions are not tracked.
This product is outside the trial-registration backfill scope. New registrations after daily collection started remain in scope. Historical rows may also be found by another product search; neither implies complete historical coverage for this product.
Public-product searches scanned: 3/30; discovered pending details: 20. Record counts in unscanned portions remain unknown.
Filings are counted by acceptance number and filing companies by first applicant. Strengths may have separate applications. Drug names are normalized only for width and whitespace; distinct generic names, dosage forms and combinations remain separate. Unstated strengths are marked. Company counts from different sources must not be added together.
Fact dates are approval dates, acceptance dates, trial first-publication dates or complete-snapshot observation dates, as applicable. Publication and site-observation dates are separate. Historical backfills are not current-period new events. Exit records cover currently inactive applications with an identifiable complete snapshot, not a full review history.
Free follow
Follow changes to Phenylephrine Hydrochloride Injection
Up to 3 drugs per email address, in one weekly digest. Starts after email confirmation; unsubscribe at any time.
Subscriptions
Next-day facts and deliverable timelines
- One email the next day when new facts are collected for your followed products.
- Export the complete loaded event timeline for each followed product as CSV.
- Add up to 4 additional recipients, each confirmed by email.
- Increase your follow limit from 3 to 10 products.
Quarterly
US$540
Billed every three months
US$180 per month
Yearly
US$1,920
Billed every year
US$160 per month
Online subscriptions are not enabled. The form below registers interest; it does not charge or activate access.
Separate one-time purchase
US Orange Book × China records comparison
Full table and CSV export for 12 months from payment, with monthly data updates. No automatic renewal.
Subscriptions and comparison-table access are purchased separately. Neither includes the other.
US$490
One payment · 12 months of access
Online comparison-table purchase is not enabled.
Billed by Creem, our merchant of record · Terms · Refund policy